What are the recommended screening, surveillance, and risk‑reduction strategies for hereditary cancer susceptibility syndromes such as BRCA1/2, Lynch syndrome, familial adenomatous polyposis, and Li‑Fraumeni?

Hereditary Cancer Susceptibility Syndromes: Screening, Surveillance, and Risk Reduction

For hereditary cancer syndromes, implement syndrome-specific intensive surveillance starting at young ages (typically 20-30 years) with colonoscopy, breast MRI, and consideration of risk-reducing surgery after childbearing is complete, as these strategies demonstrably reduce cancer mortality in high-risk populations.

BRCA1/2 Mutations (Hereditary Breast and Ovarian Cancer)

Breast Cancer Surveillance

• Begin clinical breast examination every 6-12 months starting at age 25 or 10 years before the youngest breast cancer diagnosis in the family 1
• Annual breast MRI from age 25-29 1
• Annual breast MRI AND mammography from age 30-75 1
• Avoid diagnostic radiation (CT scans) before age 30 due to increased breast cancer risk from radiation exposure 1
• If MRI unavailable, use annual mammography from age 30, though this is suboptimal 1

Ovarian Cancer Surveillance and Prevention

• Annual transvaginal ultrasound and endometrial sampling starting at age 30-35 1
• Risk-reducing bilateral salpingo-oophorectomy (RRSO) after age 35-40 once childbearing is complete - this is the most effective intervention as screening for ovarian cancer has limited sensitivity 1
• RRSO provides proven mortality benefit and should be strongly encouraged 1

Risk-Reducing Strategies

• Risk-reducing bilateral mastectomy - consider after genetic counseling, though evidence of absolute benefit requires careful discussion 1
• Encourage breastfeeding (reduces BRCA1 breast cancer risk) 1
• Maintain healthy weight, regular exercise, limit alcohol 1
• Avoid hormone replacement therapy 1

Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM mutations)

Colorectal Cancer Surveillance

• Annual colonoscopy starting at age 20-25 (or 5 years before youngest family diagnosis) 1, 2, 3
• For MSH6 mutations specifically: begin at age 30 due to later cancer onset 2
• Continue colonoscopy every 1-2 years lifelong 2
• For diagnosed colorectal cancer: perform subtotal colectomy rather than segmental resection due to high risk of metachronous cancers 2

Gynecologic Cancer Surveillance and Prevention

• Annual endometrial ultrasound ± endometrial biopsy starting at age 30-35 1, 2
• Prophylactic hysterectomy and bilateral salpingo-oophorectomy after childbearing completion - this has proven efficacy and should be strongly recommended 2

Other Organ Surveillance

• Annual urinalysis with cytology starting at age 25-35 for urinary tract cancers 2
• For populations with high gastric cancer incidence: test for and eradicate Helicobacter pylori; consider upper endoscopy every 1-3 years 3
• Annual neurological examination may be considered for CNS tumors 1

Familial Adenomatous Polyposis (FAP)

Classic FAP

• Sigmoidoscopy or colonoscopy every 1-2 years starting at age 10-11 3
• Once adenomas detected: annual colonoscopy until colectomy 3
• Colectomy is indicated when: large numbers of adenomas present, adenomas with high-grade dysplasia, or patient preference after counseling 3
• After colectomy: surveillance of remaining rectal tissue or pouch every 6-12 months 3

Upper GI Surveillance

• Gastroduodenal endoscopy (front and side-view scopes) starting when colorectal polyposis diagnosed OR at age 25-30, whichever comes first 3
• Surveillance intervals based on Spigelman staging (every 6 months to 5 years depending on polyp burden) 3

Extracolonic Manifestations

• Annual thyroid ultrasound starting at age 25-30 3
• Baseline CT or MRI if risk factors for desmoid tumors (positive family history, specific APC mutation sites) 3

Attenuated FAP (AFAP)

• Colonoscopy every 1-2 years starting at age 18-20 (later onset than classic FAP) 3
• Annual colonoscopy once adenomas detected 3
• Same upper GI and extracolonic surveillance as classic FAP 3

Li-Fraumeni Syndrome (TP53 mutations)

Comprehensive Surveillance Protocol

• Clinical breast examination every 6-12 months starting at age 20-25 1
• Annual breast MRI from age 20-75 (mammography only if MRI unavailable due to radiation concerns) 1
• Colonoscopy every 5 years from age 25 or as clinically indicated 1
• Annual dermatological examination 1
• Annual neurological examination 1
• Consider annual whole-body MRI 1
• 6-monthly complete blood count 1

Risk Reduction

• Avoid ionizing radiation (CT scans, unnecessary X-rays) - critical given TP53 mutation 1
• Consider risk-reducing mastectomy 1
• Consider pre-implantation genetic diagnosis before pregnancies 1

Other Moderate-Risk Syndromes

PALB2, CHEK2, ATM Mutations

• Clinical breast examination every 6-12 months from age 20-25 1
• Annual breast MRI from age 20-29 1
• Annual breast MRI and/or mammography from age 30-75 1
• Consider risk-reducing mastectomy 1

Peutz-Jeghers Syndrome (STK11)

• Breast surveillance as above 1
• Upper endoscopy and colonoscopy every 2-3 years from late teens 1
• Pancreatic cancer screening with EUS or MRI from age 30 1
• Annual testicular examination from childhood 1
• Annual gynecological surveillance 1

PTEN/Cowden Syndrome

• Clinical breast examination every 6-12 months from age 20-25 1
• Annual breast MRI and/or mammography from age 30-75 1
• Annual endometrial ultrasound ± biopsies from age 30-35 1
• Consider risk-reducing mastectomy and hysterectomy 1

Critical Implementation Points

Genetic Testing and Counseling

All individuals from families with known mutations who are ≥25 years old should undergo genetic testing 1. Until testing is completed or if testing is declined, follow surveillance recommendations as if mutation-positive 1.

Comprehensive pre- and post-test genetic counseling is mandatory to discuss:

• Limitations of screening (especially for ovarian cancer) 1
• Quality of life impacts of risk-reducing surgery 1
• Early-onset disease characteristics 1
• Fertility preservation options 1

Common Pitfalls to Avoid

• Inadequate family history collection - 22% of CRC patients in oncology practices had complete family history documented, and only 25% at hereditary risk were referred for genetic counseling 4
• Delayed recognition of hereditary syndromes - 25% of young-onset CRC patients have family history, 7% have hereditary syndromes, often not recognized until cancer diagnosis 4
• Poor adherence to surveillance - less than 50% of high-risk individuals adhere to risk-based screening guidelines 4
• Using mammography alone in young BRCA carriers - MRI is significantly more sensitive and is the standard of care 1

Quality Assurance

Enroll patients in dedicated high-risk follow-up clinics that specifically focus on hereditary cancer syndrome management 1. These programs should have:

• Rigorous quality assurance with benchmarking 5
• MR-guided biopsy capability 5
• Multidisciplinary coordination 1

Evidence Strength Considerations

The strongest evidence supports colonoscopic surveillance for Lynch syndrome and FAP (demonstrated mortality reduction) 2, 3, 2. Evidence for prophylactic hysterectomy/oophorectomy in Lynch syndrome and RRSO in BRCA carriers is also robust 1, 2. Breast MRI surveillance in BRCA carriers is well-established as most sensitive screening 1. However, evidence for many extracolonic surveillance strategies (e.g., whole-body MRI in Li-Fraumeni) is based on expert consensus rather than demonstrated mortality benefit 1.